The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

NCT00700817 on ClinicalTrials.gov · last registry update 2017-03-08

Finished June 2009, after enrolling 665 people. Primary outcome, as filed: Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 665
Started: 2008-06
Primary completion: 2009-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26

Conditions studied

Diabetes · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.